Quote | Unicycive Therapeutics Inc. (NASDAQ:UNCY)
Last: | $0.5011 |
---|---|
Change Percent: | -3.18% |
Open: | $0.418 |
Close: | $0.5011 |
High: | $0.5013 |
Low: | $0.401 |
Volume: | 1,607,858 |
Last Trade Date Time: | 06/28/2024 03:00:00 am |
News | Unicycive Therapeutics Inc. (NASDAQ:UNCY)
– Successfully Established Favorable Tolerability and Safety of OLC – – New Drug Application (NDA) Submission Anticipated in Q3 2024 – – Webcast and Conference Call Today at 8:30 A.M. ET – LOS ALTOS, Calif., June 25, 2024 (GLOBE NE...
– Results from Preclinical Model of Hyperphosphatemia Demonstrate the Relative Potency of OLC Compared to Tenapanor – – Oral UNI-494 Shows Promise in a Preclinical Model as a Potential Candidate for Prevention of Delayed Graft Function Related to Acute Kidney Injury...
Message Board Posts | Unicycive Therapeutics Inc. (NASDAQ:UNCY)
Subject | By | Source | When |
---|---|---|---|
Two sweet up days in a row! Keep | subslover | investorshub | 03/20/2023 5:41:25 PM |
Heading back up! | subslover | investorshub | 03/16/2023 4:10:52 PM |
Pullback today, theres alot of profit on the | harry crumb | investorshub | 03/13/2023 1:13:24 PM |
Based on its pipeline value, $1.5 is max. | Alan Brown | investorshub | 03/13/2023 6:22:47 AM |
$5.00 maybe ? | ddt60 | investorshub | 03/11/2023 5:49:33 PM |
News, Short Squeeze, Breakout and More Instantly...
Unicycive Therapeutics Inc. Company Name:
UNCY Stock Symbol:
NASDAQ Market:
– Successfully Established Favorable Tolerability and Safety of OLC – – New Drug Application (NDA) Submission Anticipated in Q3 2024 – – Webcast and Conference Call Today at 8:30 A.M. ET – LOS ALTOS, Calif., June 25, 2024 (GLOBE NE...
– Results from Preclinical Model of Hyperphosphatemia Demonstrate the Relative Potency of OLC Compared to Tenapanor – – Oral UNI-494 Shows Promise in a Preclinical Model as a Potential Candidate for Prevention of Delayed Graft Function Related to Acute Kidney Injury...
LOS ALTOS, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Ex...